<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01788163</url>
  </required_header>
  <id_info>
    <org_study_id>D7913C00074</org_study_id>
    <nct_id>NCT01788163</nct_id>
  </id_info>
  <brief_title>Asia Pacific and Russia Diagnostic Study for EGFR Testing</brief_title>
  <acronym>IGNITE</acronym>
  <official_title>A Diagnostic Study to Determine the Prevalence of EGFR Mutations in Asian and Russian Patients With Advanced NSCLC of Adenocarcinoma and Non-adenocarcinoma Histologies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional diagnostic, international, multicenter and non-comparative study of EGFR
      mutation status in aNSCLC patients (locally advanced and/or metastatic disease) with
      adenocarcinoma and non-adenocarcinoma histologies. It will be conducted in Asia Pacific and
      Russia and will assess the current status of EGFR mutation testing, and the concordance of
      EGFR mutation status derived from tumour samples and blood based circulating free DNA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A diagnostic study to determine the prevalence of EGFR mutations in Asian and Russian
      patients with advanced NSCLC of Adenocarcinoma and Non-adenocarcinoma histologies
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 27, 2013</start_date>
  <completion_date type="Actual">June 20, 2016</completion_date>
  <primary_completion_date type="Actual">August 25, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status</measure>
    <time_frame>At Screening</time_frame>
    <description>The 95% Confidence intervals were calculated using Clopper Pearson method for each country.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumour EGFR Mutation by Subtype</measure>
    <time_frame>At Screening</time_frame>
    <description>Frequency distribution of subjects with a positive mutation status by the mutation subtype and country.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumour EGFR Mutation Status by Histology</measure>
    <time_frame>At Screening</time_frame>
    <description>Only subjects who had a recorded Histological Type of Adenocarcinoma or Non-adenocarcinoma are included. Confidence intervals were calculated using Clopper Pearson method for each country.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Plasma EGFR Mutation Status</measure>
    <time_frame>At Screening</time_frame>
    <description>Plasma samples were only performed in China, Taiwan, South Korea and Russia. The Confidence intervals were calculated using Clopper Pearson method for each country.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma EGFR Mutation by Subtype</measure>
    <time_frame>At Screening</time_frame>
    <description>Plasma samples were only performed in China, Taiwan, South Korea and Russia. Frequency distribution of subjects with a positive mutation status by the mutation subtype and country.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma EGFR Mutation Status by Histology</measure>
    <time_frame>At Screening</time_frame>
    <description>Only subjects who had a recorded Histological Type of Adenocarcinoma or Non-adenocarcinoma are included. Confidence intervals were calculated using Clopper Pearson method for each country</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concordance Rate of Comparison of Mutation Status Between Tumour and Plasma Samples</measure>
    <time_frame>At Screening</time_frame>
    <description>Plasma samples were only performed in China, Taiwan, South Korea and Russia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and Specificity of Comparison of Mutation Status Between Tumour and Plasma Samples</measure>
    <time_frame>At Screening</time_frame>
    <description>Plasma samples were only performed in China, Taiwan, South Korea, and Russia. Participants only include those who had sensitivity and specificity tests performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive Values of Comparison of Mutation Status Between Tumour and Plasma Samples</measure>
    <time_frame>At Screening</time_frame>
    <description>Plasma samples were only performed in China, Taiwan, South Korea, and Russia. Participants include only those who had Positive and Negative Predictive tests performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour EGFR Mutation Testing</measure>
    <time_frame>At Screening</time_frame>
    <description>Frequencies of tumour EGFR mutation testing practices parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour EGFR Mutation Testing Rates</measure>
    <time_frame>At Screening</time_frame>
    <description>Testing Success rate is the percentage of subjects with a non-missing test result. Mutation Detection Rate is the percentage of subjects with successful test that detects a mutation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour EGFR Mutation Testing Turnaround Time</measure>
    <time_frame>At Screening</time_frame>
    <description>Tumour EGFR mutation testing turnaround time is the number of days from the test request to getting the test result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma EGFR Mutation Testing</measure>
    <time_frame>At Screening</time_frame>
    <description>Plasma samples were only performed in China, Taiwan, South Korea and Russia. Frequencies of plasma EGFR mutation testing practices parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma EGFR Mutation Testing Rates</measure>
    <time_frame>At Screening</time_frame>
    <description>Testing Success rate is the percentage of subjects with a non-missing test result. Mutation Detection Rate is the percentage of subjects with successful test that detects a mutation. Plasma samples were only performed in China, Taiwan, South Korea and Russia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma EGFR Mutation Testing Turnaround Time</measure>
    <time_frame>At Screening</time_frame>
    <description>Plasma samples were only performed in China, Taiwan, South Korea and Russia. Plasma EGFR mutation testing turnaround time is the number of days from the test request to getting the test result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demographics and Disease Characteristics by Tumour EGFR Mutation Status</measure>
    <time_frame>At Screening</time_frame>
    <description>Correlation of demographic and disease characteristics are summarized by EGFR mutation status with results from a multivariate logistic regression using stepwise forward selection with a 10% significance level for model entry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Since First Non-small-cell Lung Carcinoma (NSCLC) Diagnosis by Tumor EGFR Mutation</measure>
    <time_frame>At Screening</time_frame>
    <description>Number of months since the first diagnosis of NSCLC from informed consent date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Organs With Metastasis by Tumour EGFR Mutation Status</measure>
    <time_frame>At Screening</time_frame>
    <description>Summary of number of organs with metastasis. Only participants with at least 1 organ with metastasis are included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demographics and Disease Characteristics by Plasma EGFR Mutation Status</measure>
    <time_frame>At Screening</time_frame>
    <description>Correlation of demographic and disease characteristics are summarized by EGFR mutation status with results from a multivariate logistic regression using stepwise forward selection with a 10% significance level for model entry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Since First NSCLC Diagnosis by Plasma EGFR Mutation</measure>
    <time_frame>At Screening</time_frame>
    <description>Number of months since the first diagnosis of NSCLC from informed consent date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Organs With Metastasis by Plasma EGFR Mutation Status</measure>
    <time_frame>At Screening</time_frame>
    <description>Summary of number of organs with metastasis. Only participants with at least 1 organ with metastasis are included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Line Treatment Choice by Asia Pacific Country</measure>
    <time_frame>At Screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status</measure>
    <time_frame>At Screening</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3500</enrollment>
  <condition>EGFR Mutation Status in aNSCLC Patients</condition>
  <arm_group>
    <arm_group_label>Locally advanced/metastatic NSCLC pats.</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>EGFR mutation test</intervention_name>
    <description>EGFR mutation being tested in tissue and blood</description>
    <arm_group_label>Locally advanced/metastatic NSCLC pats.</arm_group_label>
    <other_name>Determination of EGFR mutation done at the Pathology lab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological confirmed locally advanced NSCLC (stage IIIA/B) not
             suitable for curative treatment or metastatic (stage IV) NSCLC

          -  Newly diagnosed patients with locally advanced and/or metastatic NSCLC who are
             systemic treatment Naive (i.e. no chemotherapy or EGFR-TKI) or patients with recurrent
             disease who have previously received adjuvant chemotherapy (not including EGFR-TKI)

          -  Provision of diagnostic cancer tissue or cytology sample upon inclusion (surgical
             specimen, biopsy sample, or cytology sample is acceptable) and Provision of a routine
             blood (plasma) sample in China, Russia, Taiwan and Korea

          -  Patients aged 18 years and older

        Exclusion Criteria:

          -  As judged by the investigator, any evidence of severe or uncontrolled systemic disease
             (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease)

          -  Evidence of any other significant clinical disorder or laboratory finding that made it
             undesirable for the patient to participate in the study

          -  Pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rose McCormack, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca, PHB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Campbelltown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tamworth</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wahroonga</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chengdu City</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Foshan City</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hangzhou City</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suzhou City</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan City</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Surabaya</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birobidzhan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chita</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Irkutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izhevsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Khabarovsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Khanty-Mansisk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lipetsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Obninsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orel</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perm</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Surgut</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tula</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Velikiy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vladivostok</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yakutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yuzhno-Sakhalinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Patumwan Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>Indonesia</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=599&amp;filename=D7913C00074Ignite%20Extension%20Obversational%20CSR_Synopsis.pdf</url>
    <description>D7913C00074_CSR_Synopsis</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2013</study_first_posted>
  <results_first_submitted>October 30, 2015</results_first_submitted>
  <results_first_submitted_qc>February 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2016</results_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR</keyword>
  <keyword>aNSCLC</keyword>
  <keyword>mutation status</keyword>
  <keyword>diagnostic study</keyword>
  <keyword>Russia</keyword>
  <keyword>China</keyword>
  <keyword>Asia</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Males or females that had Stage IIIB or Stage IV adenocarcinoma of the lung and who were systemic treatment naive or patients with recurrent disease who have previously received adjuvant chemotherapy were enrolled 27 February 2013 and 25 July 2014. The study was carried out in Asiapac countries and Russia.</recruitment_details>
      <pre_assignment_details>A total of 3500 patients were initially enrolled, of which 118 patients were enrolled but were excluded from the study upon failure to satisfy all eligibility criteria. These patients were not included in any analysis data sets.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>China</title>
          <description>Subjects in China that meet Inclusion/Exclusion (I/E) and population criteria.</description>
        </group>
        <group group_id="P2">
          <title>Taiwan</title>
          <description>Subjects in Taiwan that meet I/E and population criteria</description>
        </group>
        <group group_id="P3">
          <title>South Korea</title>
          <description>Subjects in South Korea that meet I/E and population criteria</description>
        </group>
        <group group_id="P4">
          <title>Australia</title>
          <description>Subjects in Australia that meet I/E and population criteria</description>
        </group>
        <group group_id="P5">
          <title>Thailand</title>
          <description>Subjects in Thailand that meet I/E and population criteria</description>
        </group>
        <group group_id="P6">
          <title>Singapore</title>
          <description>Subjects in Singapore that meet I/E and population criteria</description>
        </group>
        <group group_id="P7">
          <title>Malaysia</title>
          <description>Subjects in Malaysia that meet I/E and population criteria</description>
        </group>
        <group group_id="P8">
          <title>Indonesia</title>
          <description>Subjects in Indonesia that meet I/E and population criteria</description>
        </group>
        <group group_id="P9">
          <title>Russia</title>
          <description>Subjects in Russia that meet I/E and population criteria</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1458"/>
                <participants group_id="P2" count="271"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="71"/>
                <participants group_id="P5" count="94"/>
                <participants group_id="P6" count="102"/>
                <participants group_id="P7" count="50"/>
                <participants group_id="P8" count="302"/>
                <participants group_id="P9" count="972"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1403"/>
                <participants group_id="P2" count="271"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="71"/>
                <participants group_id="P5" count="94"/>
                <participants group_id="P6" count="95"/>
                <participants group_id="P7" count="49"/>
                <participants group_id="P8" count="254"/>
                <participants group_id="P9" count="956"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="48"/>
                <participants group_id="P9" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="48"/>
                <participants group_id="P9" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>China</title>
          <description>Subjects in China that meet I/E and population criteria.</description>
        </group>
        <group group_id="B2">
          <title>Taiwan</title>
          <description>Subjects in Taiwan that meet I/E and population criteria</description>
        </group>
        <group group_id="B3">
          <title>South Korea</title>
          <description>Subjects in South Korea that meet I/E and population criteria</description>
        </group>
        <group group_id="B4">
          <title>Australia</title>
          <description>Subjects in Australia that meet I/E and population criteria</description>
        </group>
        <group group_id="B5">
          <title>Thailand</title>
          <description>Subjects in Thailand that meet I/E and population criteria</description>
        </group>
        <group group_id="B6">
          <title>Singapore</title>
          <description>Subjects in Singapore that meet I/E and population criteria</description>
        </group>
        <group group_id="B7">
          <title>Malaysia</title>
          <description>Subjects in Malaysia that meet I/E and population criteria</description>
        </group>
        <group group_id="B8">
          <title>Indonesia</title>
          <description>Subjects in Indonesia that meet I/E and population criteria</description>
        </group>
        <group group_id="B9">
          <title>Russia</title>
          <description>Subjects in Russia that meet I/E and population criteria</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1458"/>
            <count group_id="B2" value="271"/>
            <count group_id="B3" value="62"/>
            <count group_id="B4" value="71"/>
            <count group_id="B5" value="94"/>
            <count group_id="B6" value="102"/>
            <count group_id="B7" value="50"/>
            <count group_id="B8" value="302"/>
            <count group_id="B9" value="972"/>
            <count group_id="B10" value="3382"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Calculated from birth date to screening visit date</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age (years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.8" spread="10.57"/>
                    <measurement group_id="B2" value="66.4" spread="12.66"/>
                    <measurement group_id="B3" value="65.9" spread="11.91"/>
                    <measurement group_id="B4" value="67.1" spread="10.02"/>
                    <measurement group_id="B5" value="61.2" spread="12.3"/>
                    <measurement group_id="B6" value="63.3" spread="10.79"/>
                    <measurement group_id="B7" value="58.7" spread="10.5"/>
                    <measurement group_id="B8" value="57.1" spread="11.46"/>
                    <measurement group_id="B9" value="59.8" spread="8.9"/>
                    <measurement group_id="B10" value="60.4" spread="10.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Frequency distribution of Male/Female</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="535"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="97"/>
                    <measurement group_id="B9" value="245"/>
                    <measurement group_id="B10" value="1142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="923"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="54"/>
                    <measurement group_id="B6" value="60"/>
                    <measurement group_id="B7" value="36"/>
                    <measurement group_id="B8" value="205"/>
                    <measurement group_id="B9" value="727"/>
                    <measurement group_id="B10" value="2240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status</title>
        <description>The 95% Confidence intervals were calculated using Clopper Pearson method for each country.</description>
        <time_frame>At Screening</time_frame>
        <population>Tumour Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>China</title>
            <description>Subjects in China that meet I/E and population criteria.</description>
          </group>
          <group group_id="O2">
            <title>Taiwan</title>
            <description>Subjects in Taiwan that meet I/E and population criteria</description>
          </group>
          <group group_id="O3">
            <title>South Korea</title>
            <description>Subjects in South Korea that meet I/E and population criteria</description>
          </group>
          <group group_id="O4">
            <title>Australia</title>
            <description>Subjects in Australia that meet I/E and population criteria</description>
          </group>
          <group group_id="O5">
            <title>Thailand</title>
            <description>Subjects in Thailand that meet I/E and population criteria</description>
          </group>
          <group group_id="O6">
            <title>Singapore</title>
            <description>Subjects in Singapore that meet I/E and population criteria</description>
          </group>
          <group group_id="O7">
            <title>Malaysia</title>
            <description>Subjects in Malaysia that meet I/E and population criteria</description>
          </group>
          <group group_id="O8">
            <title>Indonesia</title>
            <description>Subjects in Indonesia that meet I/E and population criteria</description>
          </group>
          <group group_id="O9">
            <title>Russia</title>
            <description>Subjects in Russia that meet I/E and population criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status</title>
          <description>The 95% Confidence intervals were calculated using Clopper Pearson method for each country.</description>
          <population>Tumour Evaluable Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1391"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="100"/>
                <count group_id="O7" value="49"/>
                <count group_id="O8" value="273"/>
                <count group_id="O9" value="924"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mutation Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" lower_limit="56.6" upper_limit="61.8"/>
                    <measurement group_id="O2" value="52.0" lower_limit="45.9" upper_limit="58.1"/>
                    <measurement group_id="O3" value="77.4" lower_limit="65.0" upper_limit="87.1"/>
                    <measurement group_id="O4" value="70.7" lower_limit="57.3" upper_limit="81.9"/>
                    <measurement group_id="O5" value="71.3" lower_limit="60.6" upper_limit="80.5"/>
                    <measurement group_id="O6" value="45.0" lower_limit="35.0" upper_limit="55.3"/>
                    <measurement group_id="O7" value="65.3" lower_limit="50.4" upper_limit="78.3"/>
                    <measurement group_id="O8" value="57.5" lower_limit="51.4" upper_limit="63.4"/>
                    <measurement group_id="O9" value="88.1" lower_limit="85.8" upper_limit="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mutation Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8" lower_limit="38.2" upper_limit="43.4"/>
                    <measurement group_id="O2" value="48.0" lower_limit="41.9" upper_limit="54.1"/>
                    <measurement group_id="O3" value="22.6" lower_limit="12.9" upper_limit="35.0"/>
                    <measurement group_id="O4" value="29.3" lower_limit="18.1" upper_limit="42.7"/>
                    <measurement group_id="O5" value="28.7" lower_limit="19.5" upper_limit="39.4"/>
                    <measurement group_id="O6" value="55.0" lower_limit="44.7" upper_limit="65.0"/>
                    <measurement group_id="O7" value="34.7" lower_limit="21.7" upper_limit="49.6"/>
                    <measurement group_id="O8" value="42.5" lower_limit="36.6" upper_limit="48.6"/>
                    <measurement group_id="O9" value="11.9" lower_limit="9.9" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumour EGFR Mutation by Subtype</title>
        <description>Frequency distribution of subjects with a positive mutation status by the mutation subtype and country.</description>
        <time_frame>At Screening</time_frame>
        <population>Tumour Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>China</title>
            <description>Subjects in China that meet I/E and population criteria.</description>
          </group>
          <group group_id="O2">
            <title>Taiwan</title>
            <description>Subjects in Taiwan that meet I/E and population criteria</description>
          </group>
          <group group_id="O3">
            <title>South Korea</title>
            <description>Subjects in South Korea that meet I/E and population criteria</description>
          </group>
          <group group_id="O4">
            <title>Australia</title>
            <description>Subjects in Australia that meet I/E and population criteria</description>
          </group>
          <group group_id="O5">
            <title>Thailand</title>
            <description>Subjects in Thailand that meet I/E and population criteria</description>
          </group>
          <group group_id="O6">
            <title>Singapore</title>
            <description>Subjects in Singapore that meet I/E and population criteria</description>
          </group>
          <group group_id="O7">
            <title>Malaysia</title>
            <description>Subjects in Malaysia that meet I/E and population criteria</description>
          </group>
          <group group_id="O8">
            <title>Indonesia</title>
            <description>Subjects in Indonesia that meet I/E and population criteria</description>
          </group>
          <group group_id="O9">
            <title>Russia</title>
            <description>Subjects in Russia that meet I/E and population criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Tumour EGFR Mutation by Subtype</title>
          <description>Frequency distribution of subjects with a positive mutation status by the mutation subtype and country.</description>
          <population>Tumour Evaluable Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1391"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="100"/>
                <count group_id="O7" value="49"/>
                <count group_id="O8" value="273"/>
                <count group_id="O9" value="924"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G719x mutation only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exon 19 deletion only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="43"/>
                    <measurement group_id="O9" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exon 19 deletion +T790M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exon 19 deletion + other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exon 19 Other only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T790M only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T790M + other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exon 20 insertions only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L858R mutation only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="70"/>
                    <measurement group_id="O9" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S768I mutation only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L858R mutation + other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L861Q mutation only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exon 21 Other only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumour EGFR Mutation Status by Histology</title>
        <description>Only subjects who had a recorded Histological Type of Adenocarcinoma or Non-adenocarcinoma are included. Confidence intervals were calculated using Clopper Pearson method for each country.</description>
        <time_frame>At Screening</time_frame>
        <population>Tumour Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>China-Adenocarcinoma</title>
            <description>Subjects in China that meet I/E and population criteria with a histological type of Adenocarcinoma.</description>
          </group>
          <group group_id="O2">
            <title>China-Non-adenocarcinoma</title>
            <description>Subjects in China that meet I/E and population criteria with a histological type of Non-Adenocarcinoma.</description>
          </group>
          <group group_id="O3">
            <title>Taiwan-Adenocarcinoma</title>
            <description>Subjects in Taiwan that meet I/E and population criteria with a histological type of Adenocarcinoma.</description>
          </group>
          <group group_id="O4">
            <title>Taiwan-Non-adenocarcinoma</title>
            <description>Subjects in Taiwan that meet I/E and population criteria with a histological type of Non-Adenocarcinoma.</description>
          </group>
          <group group_id="O5">
            <title>South Korea-Adenocarcinoma</title>
            <description>Subjects in South Korea that meet I/E and population criteria with a histological type of Adenocarcinoma.</description>
          </group>
          <group group_id="O6">
            <title>South Korea-Non-adenocarcinoma</title>
            <description>Subjects in South Korea that meet I/E and population criteria with a histological type of Non-Adenocarcinoma.</description>
          </group>
          <group group_id="O7">
            <title>Australia-Adenocarcinoma</title>
            <description>Subjects in Australia that meet I/E and population criteria with a histological type of Adenocarcinoma.</description>
          </group>
          <group group_id="O8">
            <title>Australia-Non-adenocarcinoma</title>
            <description>Subjects in Australia that meet I/E and population criteria with a histological type of Non-Adenocarcinoma.</description>
          </group>
          <group group_id="O9">
            <title>Thailand-Adenocarcinoma</title>
            <description>Subjects in Thailand that meet I/E and population criteria with a histological type of Adenocarcinoma.</description>
          </group>
          <group group_id="O10">
            <title>Thailand-Non-adenocarcinoma</title>
            <description>Subjects in Thailand that meet I/E and population criteria with a histological type of Non-Adenocarcinoma.</description>
          </group>
          <group group_id="O11">
            <title>Singapore-Adenocarcinoma</title>
            <description>Subjects in Singapore that meet I/E and population criteria with a histological type of Adenocarcinoma.</description>
          </group>
          <group group_id="O12">
            <title>Singapore-Non-adenocarcinoma</title>
            <description>Subjects in Singapore that meet I/E and population criteria with a histological type of Non-Adenocarcinoma.</description>
          </group>
          <group group_id="O13">
            <title>Malaysia-Adenocarcinoma</title>
            <description>Subjects in Malaysia that meet I/E and population criteria with a histological type of Adenocarcinoma.</description>
          </group>
          <group group_id="O14">
            <title>Malaysia-Non-adenocarcinoma</title>
            <description>Subjects in Malaysia that meet I/E and population criteria with a histological type of Non-Adenocarcinoma.</description>
          </group>
          <group group_id="O15">
            <title>Indonesia-Adenocarcinoma</title>
            <description>Subjects in Indonesia that meet I/E and population criteria with a histological type of Adenocarcinoma.</description>
          </group>
          <group group_id="O16">
            <title>Indonesia-Non-adenocarcinoma</title>
            <description>Subjects in Indonesia that meet I/E and population criteria with a histological type of Non-Adenocarcinoma.</description>
          </group>
          <group group_id="O17">
            <title>Russia-Adenocarcinoma</title>
            <description>Subjects in Russia that meet I/E and population criteria with a histological type of Adenocarcinoma.</description>
          </group>
          <group group_id="O18">
            <title>Russia-Non-adenocarcinoma</title>
            <description>Subjects in Russia that meet I/E and population criteria with a histological type of Non-Adenocarcinoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Tumour EGFR Mutation Status by Histology</title>
          <description>Only subjects who had a recorded Histological Type of Adenocarcinoma or Non-adenocarcinoma are included. Confidence intervals were calculated using Clopper Pearson method for each country.</description>
          <population>Tumour Evaluable Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1026"/>
                <count group_id="O2" value="361"/>
                <count group_id="O3" value="208"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="49"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="73"/>
                <count group_id="O10" value="13"/>
                <count group_id="O11" value="95"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="40"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="212"/>
                <count group_id="O16" value="59"/>
                <count group_id="O17" value="500"/>
                <count group_id="O18" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mutation Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7" lower_limit="45.6" upper_limit="51.8"/>
                    <measurement group_id="O2" value="88.9" lower_limit="85.2" upper_limit="92.0"/>
                    <measurement group_id="O3" value="42.8" lower_limit="36.0" upper_limit="49.8"/>
                    <measurement group_id="O4" value="83.6" lower_limit="71.9" upper_limit="91.8"/>
                    <measurement group_id="O5" value="69.6" lower_limit="54.2" upper_limit="82.3"/>
                    <measurement group_id="O6" value="100.0" lower_limit="78.2" upper_limit="100.0"/>
                    <measurement group_id="O7" value="67.3" lower_limit="52.5" upper_limit="80.1"/>
                    <measurement group_id="O8" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                    <measurement group_id="O9" value="69.9" lower_limit="58.0" upper_limit="80.1"/>
                    <measurement group_id="O10" value="84.6" lower_limit="54.6" upper_limit="98.1"/>
                    <measurement group_id="O11" value="43.2" lower_limit="33.0" upper_limit="53.7"/>
                    <measurement group_id="O12" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                    <measurement group_id="O13" value="62.5" lower_limit="45.8" upper_limit="77.3"/>
                    <measurement group_id="O14" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O15" value="54.7" lower_limit="47.8" upper_limit="61.5"/>
                    <measurement group_id="O16" value="67.8" lower_limit="54.4" upper_limit="79.4"/>
                    <measurement group_id="O17" value="82.0" lower_limit="78.3" upper_limit="85.3"/>
                    <measurement group_id="O18" value="96.3" lower_limit="93.9" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mutation Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3" lower_limit="48.2" upper_limit="54.4"/>
                    <measurement group_id="O2" value="11.1" lower_limit="8.0" upper_limit="14.8"/>
                    <measurement group_id="O3" value="57.2" lower_limit="50.2" upper_limit="64.0"/>
                    <measurement group_id="O4" value="16.4" lower_limit="8.2" upper_limit="28.1"/>
                    <measurement group_id="O5" value="30.4" lower_limit="17.7" upper_limit="45.8"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="21.8"/>
                    <measurement group_id="O7" value="32.7" lower_limit="19.9" upper_limit="47.5"/>
                    <measurement group_id="O8" value="14.3" lower_limit="0.4" upper_limit="57.9"/>
                    <measurement group_id="O9" value="30.1" lower_limit="19.9" upper_limit="42.0"/>
                    <measurement group_id="O10" value="15.4" lower_limit="1.9" upper_limit="45.4"/>
                    <measurement group_id="O11" value="56.8" lower_limit="46.3" upper_limit="67.0"/>
                    <measurement group_id="O12" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                    <measurement group_id="O13" value="37.5" lower_limit="22.7" upper_limit="54.2"/>
                    <measurement group_id="O14" value="16.7" lower_limit="0.4" upper_limit="64.1"/>
                    <measurement group_id="O15" value="45.3" lower_limit="38.5" upper_limit="52.2"/>
                    <measurement group_id="O16" value="32.2" lower_limit="20.6" upper_limit="45.6"/>
                    <measurement group_id="O17" value="18.0" lower_limit="14.7" upper_limit="21.7"/>
                    <measurement group_id="O18" value="3.7" lower_limit="2.1" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Plasma EGFR Mutation Status</title>
        <description>Plasma samples were only performed in China, Taiwan, South Korea and Russia. The Confidence intervals were calculated using Clopper Pearson method for each country.</description>
        <time_frame>At Screening</time_frame>
        <population>Plasma Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>China</title>
            <description>Subjects in China that meet I/E and population criteria.</description>
          </group>
          <group group_id="O2">
            <title>Taiwan</title>
            <description>Subjects in Taiwan that meet I/E and population criteria</description>
          </group>
          <group group_id="O3">
            <title>South Korea</title>
            <description>Subjects in South Korea that meet I/E and population criteria</description>
          </group>
          <group group_id="O4">
            <title>Russia</title>
            <description>Subjects in Russia that meet I/E and population criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Plasma EGFR Mutation Status</title>
          <description>Plasma samples were only performed in China, Taiwan, South Korea and Russia. The Confidence intervals were calculated using Clopper Pearson method for each country.</description>
          <population>Plasma Evaluable Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1421"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="941"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mutation Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3" lower_limit="77.1" upper_limit="81.4"/>
                    <measurement group_id="O2" value="73.1" lower_limit="67.4" upper_limit="78.3"/>
                    <measurement group_id="O3" value="86.9" lower_limit="75.8" upper_limit="94.2"/>
                    <measurement group_id="O4" value="90.8" lower_limit="88.7" upper_limit="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mutation Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" lower_limit="18.6" upper_limit="22.9"/>
                    <measurement group_id="O2" value="26.9" lower_limit="21.7" upper_limit="32.6"/>
                    <measurement group_id="O3" value="13.1" lower_limit="5.8" upper_limit="24.2"/>
                    <measurement group_id="O4" value="9.2" lower_limit="7.5" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma EGFR Mutation by Subtype</title>
        <description>Plasma samples were only performed in China, Taiwan, South Korea and Russia. Frequency distribution of subjects with a positive mutation status by the mutation subtype and country.</description>
        <time_frame>At Screening</time_frame>
        <population>Plasma Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>China</title>
            <description>Subjects in China that meet I/E and population criteria.</description>
          </group>
          <group group_id="O2">
            <title>Taiwan</title>
            <description>Subjects in Taiwan that meet I/E and population criteria</description>
          </group>
          <group group_id="O3">
            <title>South Korea</title>
            <description>Subjects in South Korea that meet I/E and population criteria</description>
          </group>
          <group group_id="O4">
            <title>Russia</title>
            <description>Subjects in Russia that meet I/E and population criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma EGFR Mutation by Subtype</title>
          <description>Plasma samples were only performed in China, Taiwan, South Korea and Russia. Frequency distribution of subjects with a positive mutation status by the mutation subtype and country.</description>
          <population>Plasma Evaluable Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1421"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="941"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G719X mutation only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exon 19 deletion only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exon 19 deletion + other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T790M + other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exon 20 insertions only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L858R mutation only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S768I mutation only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L858R mutation + Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L861Q mutation only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma EGFR Mutation Status by Histology</title>
        <description>Only subjects who had a recorded Histological Type of Adenocarcinoma or Non-adenocarcinoma are included. Confidence intervals were calculated using Clopper Pearson method for each country</description>
        <time_frame>At Screening</time_frame>
        <population>Plasma Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>China-Adenocarcinoma</title>
            <description>Subjects in China that meet I/E and population criteria with a histological type of Adenocarcinoma.</description>
          </group>
          <group group_id="O2">
            <title>China-Non-Adenocarcinoma</title>
            <description>Subjects in China that meet I/E and population criteria with a histological type of Non-Adenocarcinoma.</description>
          </group>
          <group group_id="O3">
            <title>Taiwan-Adenocarcinoma</title>
            <description>Subjects in Taiwan that meet I/E and population criteria with a histological type of Adenocarcinoma.</description>
          </group>
          <group group_id="O4">
            <title>Taiwan-Non-adenocarcinoma</title>
            <description>Subjects in Taiwan that meet I/E and population criteria with a histological type of Non-Adenocarcinoma.</description>
          </group>
          <group group_id="O5">
            <title>South Korea-Adenocarcinoma</title>
            <description>Subjects in South Korea that meet I/E and population criteria with a histological type of Adenocarcinoma.</description>
          </group>
          <group group_id="O6">
            <title>South Korea-Non-adenocarcinoma</title>
            <description>Subjects in South Korea that meet I/E and population criteria with a histological type of Non-Adenocarcinoma.</description>
          </group>
          <group group_id="O7">
            <title>Russia-Adenocarcinoma</title>
            <description>Subjects in Russia that meet I/E and population criteria with a histological type of Adenocarcinoma.</description>
          </group>
          <group group_id="O8">
            <title>Russia-Non-adenocarcinoma</title>
            <description>Subjects in Russia that meet I/E and population criteria with a histological type of Non-Adenocarcinoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma EGFR Mutation Status by Histology</title>
          <description>Only subjects who had a recorded Histological Type of Adenocarcinoma or Non-adenocarcinoma are included. Confidence intervals were calculated using Clopper Pearson method for each country</description>
          <population>Plasma Evaluable Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1047"/>
                <count group_id="O2" value="369"/>
                <count group_id="O3" value="208"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="513"/>
                <count group_id="O8" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mutation Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" lower_limit="71.6" upper_limit="77.0"/>
                    <measurement group_id="O2" value="93.2" lower_limit="90.2" upper_limit="95.6"/>
                    <measurement group_id="O3" value="68.3" lower_limit="61.5" upper_limit="74.5"/>
                    <measurement group_id="O4" value="90.2" lower_limit="79.8" upper_limit="96.3"/>
                    <measurement group_id="O5" value="82.6" lower_limit="68.6" upper_limit="92.2"/>
                    <measurement group_id="O6" value="100.0" lower_limit="78.2" upper_limit="100.0"/>
                    <measurement group_id="O7" value="89.3" lower_limit="86.3" upper_limit="91.8"/>
                    <measurement group_id="O8" value="92.9" lower_limit="90.0" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mutation Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" lower_limit="23.0" upper_limit="28.4"/>
                    <measurement group_id="O2" value="6.8" lower_limit="4.4" upper_limit="9.8"/>
                    <measurement group_id="O3" value="31.7" lower_limit="25.5" upper_limit="38.5"/>
                    <measurement group_id="O4" value="9.8" lower_limit="3.7" upper_limit="20.2"/>
                    <measurement group_id="O5" value="17.4" lower_limit="7.8" upper_limit="31.4"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="21.8"/>
                    <measurement group_id="O7" value="10.7" lower_limit="8.2" upper_limit="13.7"/>
                    <measurement group_id="O8" value="7.1" lower_limit="4.8" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concordance Rate of Comparison of Mutation Status Between Tumour and Plasma Samples</title>
        <description>Plasma samples were only performed in China, Taiwan, South Korea and Russia.</description>
        <time_frame>At Screening</time_frame>
        <population>Tumour and Plasma Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>China</title>
            <description>Subjects in China that meet I/E and population criteria.</description>
          </group>
          <group group_id="O2">
            <title>Taiwan</title>
            <description>Subjects in Taiwan that meet I/E and population criteria</description>
          </group>
          <group group_id="O3">
            <title>South Korea</title>
            <description>Subjects in South Korea that meet I/E and population criteria</description>
          </group>
          <group group_id="O4">
            <title>Russia</title>
            <description>Subjects in Russia that meet I/E and population criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Concordance Rate of Comparison of Mutation Status Between Tumour and Plasma Samples</title>
          <description>Plasma samples were only performed in China, Taiwan, South Korea and Russia.</description>
          <population>Tumour and Plasma Evaluable Population</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1355"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="894"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" lower_limit="75.2" upper_limit="79.8"/>
                    <measurement group_id="O2" value="76.8" lower_limit="71.3" upper_limit="81.6"/>
                    <measurement group_id="O3" value="83.6" lower_limit="71.9" upper_limit="91.8"/>
                    <measurement group_id="O4" value="85.8" lower_limit="83.3" upper_limit="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity and Specificity of Comparison of Mutation Status Between Tumour and Plasma Samples</title>
        <description>Plasma samples were only performed in China, Taiwan, South Korea, and Russia. Participants only include those who had sensitivity and specificity tests performed.</description>
        <time_frame>At Screening</time_frame>
        <population>Tumour and Plasma Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>China - Sensitivity</title>
            <description>Subjects in China that meet I/E and population criteria, who had a sensitivity test performed.</description>
          </group>
          <group group_id="O2">
            <title>China - Specificty</title>
            <description>Subjects in China that meet I/E and population criteria, who had a specificity test performed.</description>
          </group>
          <group group_id="O3">
            <title>Taiwan - Sensitivity</title>
            <description>Subjects in Taiwan that meet I/E and population criteria, who had a sensitivity test performed.</description>
          </group>
          <group group_id="O4">
            <title>Taiwan - Specificity</title>
            <description>Subjects in Taiwan that meet I/E and population criteria, who had a specificity test performed.</description>
          </group>
          <group group_id="O5">
            <title>South Korea - Sensitivity</title>
            <description>Subjects in South Korea that meet I/E and population criteria, who had a sensitivity test performed.</description>
          </group>
          <group group_id="O6">
            <title>South Korea - Specificity</title>
            <description>Subjects in South Korea that meet I/E and population criteria, who had a specificity test performed.</description>
          </group>
          <group group_id="O7">
            <title>Russia - Sensitivity</title>
            <description>Subjects in Russia that meet I/E and population criteria, who had a sensitivity test performed.</description>
          </group>
          <group group_id="O8">
            <title>Russia - Specificity</title>
            <description>Subjects in Russia that meet I/E and population criteria, who had a specificity test performed.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity and Specificity of Comparison of Mutation Status Between Tumour and Plasma Samples</title>
          <description>Plasma samples were only performed in China, Taiwan, South Korea, and Russia. Participants only include those who had sensitivity and specificity tests performed.</description>
          <population>Tumour and Plasma Evaluable Population</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="548"/>
                <count group_id="O2" value="807"/>
                <count group_id="O3" value="130"/>
                <count group_id="O4" value="141"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="47"/>
                <count group_id="O7" value="109"/>
                <count group_id="O8" value="785"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7"/>
                    <measurement group_id="O2" value="97.1"/>
                    <measurement group_id="O3" value="53.8"/>
                    <measurement group_id="O4" value="97.9"/>
                    <measurement group_id="O5" value="42.9"/>
                    <measurement group_id="O6" value="95.7"/>
                    <measurement group_id="O7" value="30.3"/>
                    <measurement group_id="O8" value="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predictive Values of Comparison of Mutation Status Between Tumour and Plasma Samples</title>
        <description>Plasma samples were only performed in China, Taiwan, South Korea, and Russia. Participants include only those who had Positive and Negative Predictive tests performed.</description>
        <time_frame>At Screening</time_frame>
        <population>Tumour and Plasma Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>China - Positive Predictive Value</title>
            <description>Subjects in China that meet I/E and population criteria, who had a Positive Predictive test performed.</description>
          </group>
          <group group_id="O2">
            <title>China - Negative Predictive Value</title>
            <description>Subjects in China that meet I/E and population criteria, who had a Negative Predictive test performed.</description>
          </group>
          <group group_id="O3">
            <title>Taiwan - Positive Predictive Value</title>
            <description>Subjects in Taiwan that meet I/E and population criteria, who had a Positive Predictive test performed.</description>
          </group>
          <group group_id="O4">
            <title>Taiwan - Negative Predictive Value</title>
            <description>Subjects in Taiwan that meet I/E and population criteria, who had a Negative Predictive test performed.</description>
          </group>
          <group group_id="O5">
            <title>South Korea - Positive Predictive Value</title>
            <description>Subjects in South Korea that meet I/E and population criteria, who had a Positive Predictive test performed.</description>
          </group>
          <group group_id="O6">
            <title>South Korea - Negative Predictive Value</title>
            <description>Subjects in South Korea that meet I/E and population criteria, who had a Negative Predictive test performed.</description>
          </group>
          <group group_id="O7">
            <title>Russia - Positive Predictive Value</title>
            <description>Subjects in Russia that meet I/E and population criteria, who had a Positive Predictive test performed.</description>
          </group>
          <group group_id="O8">
            <title>Russia - Negative Predictive Value</title>
            <description>Subjects in Russia that meet I/E and population criteria, who had a Negative Predictive test performed.</description>
          </group>
        </group_list>
        <measure>
          <title>Predictive Values of Comparison of Mutation Status Between Tumour and Plasma Samples</title>
          <description>Plasma samples were only performed in China, Taiwan, South Korea, and Russia. Participants include only those who had Positive and Negative Predictive tests performed.</description>
          <population>Tumour and Plasma Evaluable Population</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="1065"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="198"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="53"/>
                <count group_id="O7" value="84"/>
                <count group_id="O8" value="810"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1"/>
                    <measurement group_id="O2" value="73.6"/>
                    <measurement group_id="O3" value="95.9"/>
                    <measurement group_id="O4" value="69.7"/>
                    <measurement group_id="O5" value="75.0"/>
                    <measurement group_id="O6" value="84.9"/>
                    <measurement group_id="O7" value="39.3"/>
                    <measurement group_id="O8" value="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumour EGFR Mutation Testing</title>
        <description>Frequencies of tumour EGFR mutation testing practices parameters.</description>
        <time_frame>At Screening</time_frame>
        <population>Enrolled Population</population>
        <group_list>
          <group group_id="O1">
            <title>China</title>
            <description>Subjects in China that meet I/E and population criteria.</description>
          </group>
          <group group_id="O2">
            <title>Taiwan</title>
            <description>Subjects in Taiwan that meet I/E and population criteria</description>
          </group>
          <group group_id="O3">
            <title>South Korea</title>
            <description>Subjects in South Korea that meet I/E and population criteria</description>
          </group>
          <group group_id="O4">
            <title>Australia</title>
            <description>Subjects in Australia that meet I/E and population criteria</description>
          </group>
          <group group_id="O5">
            <title>Thailand</title>
            <description>Subjects in Thailand that meet I/E and population criteria</description>
          </group>
          <group group_id="O6">
            <title>Singapore</title>
            <description>Subjects in Singapore that meet I/E and population criteria</description>
          </group>
          <group group_id="O7">
            <title>Malaysia</title>
            <description>Subjects in Malaysia that meet I/E and population criteria</description>
          </group>
          <group group_id="O8">
            <title>Indonesia</title>
            <description>Subjects in Indonesia that meet I/E and population criteria</description>
          </group>
          <group group_id="O9">
            <title>Russia</title>
            <description>Subjects in Russia that meet I/E and population criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Tumour EGFR Mutation Testing</title>
          <description>Frequencies of tumour EGFR mutation testing practices parameters.</description>
          <population>Enrolled Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1458"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="94"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="302"/>
                <count group_id="O9" value="972"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tumour Sample</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1394"/>
                    <measurement group_id="O2" value="271"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="60"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="101"/>
                    <measurement group_id="O7" value="49"/>
                    <measurement group_id="O8" value="273"/>
                    <measurement group_id="O9" value="936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mutation Test Not Performed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="29"/>
                    <measurement group_id="O9" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumour EGFR Mutation Testing Rates</title>
        <description>Testing Success rate is the percentage of subjects with a non-missing test result. Mutation Detection Rate is the percentage of subjects with successful test that detects a mutation.</description>
        <time_frame>At Screening</time_frame>
        <population>Enrolled Population</population>
        <group_list>
          <group group_id="O1">
            <title>China</title>
            <description>Subjects in China that meet I/E and population criteria.</description>
          </group>
          <group group_id="O2">
            <title>Taiwan</title>
            <description>Subjects in Taiwan that meet I/E and population criteria</description>
          </group>
          <group group_id="O3">
            <title>South Korea</title>
            <description>Subjects in South Korea that meet I/E and population criteria</description>
          </group>
          <group group_id="O4">
            <title>Australia</title>
            <description>Subjects in Australia that meet I/E and population criteria</description>
          </group>
          <group group_id="O5">
            <title>Thailand</title>
            <description>Subjects in Thailand that meet I/E and population criteria</description>
          </group>
          <group group_id="O6">
            <title>Singapore</title>
            <description>Subjects in Singapore that meet I/E and population criteria</description>
          </group>
          <group group_id="O7">
            <title>Malaysia</title>
            <description>Subjects in Malaysia that meet I/E and population criteria</description>
          </group>
          <group group_id="O8">
            <title>Indonesia</title>
            <description>Subjects in Indonesia that meet I/E and population criteria</description>
          </group>
          <group group_id="O9">
            <title>Russia</title>
            <description>Subjects in Russia that meet I/E and population criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Tumour EGFR Mutation Testing Rates</title>
          <description>Testing Success rate is the percentage of subjects with a non-missing test result. Mutation Detection Rate is the percentage of subjects with successful test that detects a mutation.</description>
          <population>Enrolled Population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1458"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="94"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="302"/>
                <count group_id="O9" value="972"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testing Success Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="96.7"/>
                    <measurement group_id="O5" value="94.6"/>
                    <measurement group_id="O6" value="99.0"/>
                    <measurement group_id="O7" value="100.0"/>
                    <measurement group_id="O8" value="100.0"/>
                    <measurement group_id="O9" value="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mutation Detection Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7"/>
                    <measurement group_id="O2" value="48.0"/>
                    <measurement group_id="O3" value="24.2"/>
                    <measurement group_id="O4" value="28.3"/>
                    <measurement group_id="O5" value="27.2"/>
                    <measurement group_id="O6" value="54.5"/>
                    <measurement group_id="O7" value="34.7"/>
                    <measurement group_id="O8" value="42.5"/>
                    <measurement group_id="O9" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumour EGFR Mutation Testing Turnaround Time</title>
        <description>Tumour EGFR mutation testing turnaround time is the number of days from the test request to getting the test result.</description>
        <time_frame>At Screening</time_frame>
        <population>Enrolled Population</population>
        <group_list>
          <group group_id="O1">
            <title>China</title>
            <description>Subjects in China that meet I/E and population criteria.</description>
          </group>
          <group group_id="O2">
            <title>Taiwan</title>
            <description>Subjects in Taiwan that meet I/E and population criteria</description>
          </group>
          <group group_id="O3">
            <title>South Korea</title>
            <description>Subjects in South Korea that meet I/E and population criteria</description>
          </group>
          <group group_id="O4">
            <title>Australia</title>
            <description>Subjects in Australia that meet I/E and population criteria</description>
          </group>
          <group group_id="O5">
            <title>Thailand</title>
            <description>Subjects in Thailand that meet I/E and population criteria</description>
          </group>
          <group group_id="O6">
            <title>Singapore</title>
            <description>Subjects in Singapore that meet I/E and population criteria</description>
          </group>
          <group group_id="O7">
            <title>Malaysia</title>
            <description>Subjects in Malaysia that meet I/E and population criteria</description>
          </group>
          <group group_id="O8">
            <title>Indonesia</title>
            <description>Subjects in Indonesia that meet I/E and population criteria</description>
          </group>
          <group group_id="O9">
            <title>Russia</title>
            <description>Subjects in Russia that meet I/E and population criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Tumour EGFR Mutation Testing Turnaround Time</title>
          <description>Tumour EGFR mutation testing turnaround time is the number of days from the test request to getting the test result.</description>
          <population>Enrolled Population</population>
          <units>Time (Days)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1458"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="94"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="302"/>
                <count group_id="O9" value="972"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="5.34"/>
                    <measurement group_id="O2" value="7.4" spread="12.29"/>
                    <measurement group_id="O3" value="11.7" spread="12.70"/>
                    <measurement group_id="O4" value="12.9" spread="8.19"/>
                    <measurement group_id="O5" value="70.8" spread="43.85"/>
                    <measurement group_id="O6" value="8.4" spread="4.90"/>
                    <measurement group_id="O7" value="8.6" spread="3.55"/>
                    <measurement group_id="O8" value="6.5" spread="2.33"/>
                    <measurement group_id="O9" value="14.3" spread="26.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma EGFR Mutation Testing</title>
        <description>Plasma samples were only performed in China, Taiwan, South Korea and Russia. Frequencies of plasma EGFR mutation testing practices parameters.</description>
        <time_frame>At Screening</time_frame>
        <population>Enrolled Population</population>
        <group_list>
          <group group_id="O1">
            <title>China</title>
            <description>Subjects in China that meet I/E and population criteria.</description>
          </group>
          <group group_id="O2">
            <title>Taiwan</title>
            <description>Subjects in Taiwan that meet I/E and population criteria</description>
          </group>
          <group group_id="O3">
            <title>South Korea</title>
            <description>Subjects in South Korea that meet I/E and population criteria</description>
          </group>
          <group group_id="O4">
            <title>Russia</title>
            <description>Subjects in Russia that meet I/E and population criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma EGFR Mutation Testing</title>
          <description>Plasma samples were only performed in China, Taiwan, South Korea and Russia. Frequencies of plasma EGFR mutation testing practices parameters.</description>
          <population>Enrolled Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1458"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="972"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma Sample</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1421"/>
                    <measurement group_id="O2" value="271"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mutation Test Not performed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma EGFR Mutation Testing Rates</title>
        <description>Testing Success rate is the percentage of subjects with a non-missing test result. Mutation Detection Rate is the percentage of subjects with successful test that detects a mutation. Plasma samples were only performed in China, Taiwan, South Korea and Russia.</description>
        <time_frame>At Screening</time_frame>
        <population>Enrolled Population</population>
        <group_list>
          <group group_id="O1">
            <title>China</title>
            <description>Subjects in China that meet I/E and population criteria.</description>
          </group>
          <group group_id="O2">
            <title>Taiwan</title>
            <description>Subjects in Taiwan that meet I/E and population criteria</description>
          </group>
          <group group_id="O3">
            <title>South Korea</title>
            <description>Subjects in South Korea that meet I/E and population criteria</description>
          </group>
          <group group_id="O4">
            <title>Russia</title>
            <description>Subjects in Russia that meet I/E and population criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma EGFR Mutation Testing Rates</title>
          <description>Testing Success rate is the percentage of subjects with a non-missing test result. Mutation Detection Rate is the percentage of subjects with successful test that detects a mutation. Plasma samples were only performed in China, Taiwan, South Korea and Russia.</description>
          <population>Enrolled Population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1458"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="972"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testing Success Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="98.4"/>
                    <measurement group_id="O4" value="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mutation Detection Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="26.9"/>
                    <measurement group_id="O3" value="12.9"/>
                    <measurement group_id="O4" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma EGFR Mutation Testing Turnaround Time</title>
        <description>Plasma samples were only performed in China, Taiwan, South Korea and Russia. Plasma EGFR mutation testing turnaround time is the number of days from the test request to getting the test result.</description>
        <time_frame>At Screening</time_frame>
        <population>Enrolled Population</population>
        <group_list>
          <group group_id="O1">
            <title>China</title>
            <description>Subjects in China that meet I/E and population criteria</description>
          </group>
          <group group_id="O2">
            <title>Taiwan</title>
            <description>Subjects in Taiwan that meet I/E and population criteria</description>
          </group>
          <group group_id="O3">
            <title>South Korea</title>
            <description>Subjects in South Korea that meet I/E and population criteria</description>
          </group>
          <group group_id="O4">
            <title>Russia</title>
            <description>Subjects in Russia that meet I/E and population criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma EGFR Mutation Testing Turnaround Time</title>
          <description>Plasma samples were only performed in China, Taiwan, South Korea and Russia. Plasma EGFR mutation testing turnaround time is the number of days from the test request to getting the test result.</description>
          <population>Enrolled Population</population>
          <units>Time (Days)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1458"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="972"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" spread="44.24"/>
                    <measurement group_id="O2" value="26.7" spread="12.62"/>
                    <measurement group_id="O3" value="18.1" spread="13.72"/>
                    <measurement group_id="O4" value="90.1" spread="105.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Demographics and Disease Characteristics by Tumour EGFR Mutation Status</title>
        <description>Correlation of demographic and disease characteristics are summarized by EGFR mutation status with results from a multivariate logistic regression using stepwise forward selection with a 10% significance level for model entry.</description>
        <time_frame>At Screening</time_frame>
        <population>Tumour Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>EGFR Mutation Positive</title>
            <description>Participants who were EGFR Mutation Positive for the analysis population.</description>
          </group>
          <group group_id="O2">
            <title>EGFR Mutation Negative</title>
            <description>Participants who were EGFR Mutation Negative for the analysis population.</description>
          </group>
        </group_list>
        <measure>
          <title>Demographics and Disease Characteristics by Tumour EGFR Mutation Status</title>
          <description>Correlation of demographic and disease characteristics are summarized by EGFR mutation status with results from a multivariate logistic regression using stepwise forward selection with a 10% significance level for model entry.</description>
          <population>Tumour Evaluable Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1051"/>
                <count group_id="O2" value="2164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Histology: Adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="952"/>
                    <measurement group_id="O2" value="1297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histology: Non-adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Status: Never-Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="705"/>
                    <measurement group_id="O2" value="647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Status: Ever-Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="346"/>
                    <measurement group_id="O2" value="1517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gender: Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="480"/>
                    <measurement group_id="O2" value="1647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gender: Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="571"/>
                    <measurement group_id="O2" value="517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Region: Asia Pacific</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="941"/>
                    <measurement group_id="O2" value="1350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Region: Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age: &lt;=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="695"/>
                    <measurement group_id="O2" value="1447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356"/>
                    <measurement group_id="O2" value="717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>World Health Organization Performance Status: 0-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="866"/>
                    <measurement group_id="O2" value="1808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>World Health Organization Performance Status: 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Disease Status: IIIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Disease Status: IIIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Disease Status: IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="923"/>
                    <measurement group_id="O2" value="1527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Organs with Metastasis = 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458"/>
                    <measurement group_id="O2" value="901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Organs with Metastasis = 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266"/>
                    <measurement group_id="O2" value="408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Organs with Metastasis = 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Organs with Metastasis = 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Organs with Metastasis = 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Organs with Metastasis = 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Organs with Metastasis = 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Histology: Adenocarcinoma vs Non-adenocarcinoma</p_value_desc>
            <method>Regression stepwise</method>
            <method_desc>10% significance level for entry criteria</method_desc>
            <param_type>Wald Chi Square Statistic</param_type>
            <param_value>81.1237</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Histology: Adenocarcinoma vs Non-adenocarcinoma</p_value_desc>
            <method>Regression stepwise</method>
            <method_desc>10% significance level for model entry</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.973</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0075</p_value>
            <p_value_desc>Gender: Male vs. Female</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% significance level for entry criteria</method_desc>
            <param_type>Wald Chi Square Statistic</param_type>
            <param_value>7.1526</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0075</p_value>
            <p_value_desc>Gender: Male vs. Female</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% Significance Level for model entry</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.409</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Smoking Status: Never-smoker vs. Ever-smoker</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% significance level for entry criteria</method_desc>
            <param_type>Wald Chi Square Statistic</param_type>
            <param_value>51.8456</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Smoking Status: Never-smoker vs. Ever-smoker</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% Significance Level for model entry</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.515</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Region: Asia Pacific vs. Russia</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% Significance Level for entry criteria</method_desc>
            <param_type>Wald Chi Square Statistic</param_type>
            <param_value>98.1065</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Region: Asia Pacific vs. Russia</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% Significance Level for model entry</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.929</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0909</p_value>
            <p_value_desc>Number of organs with metastasis</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% significance level for entry criteria</method_desc>
            <param_type>Wald Chi Square Statistic</param_type>
            <param_value>2.8589</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0909</p_value>
            <p_value_desc>Number of organs with metastasis</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% significance level for model entry</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.086</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Since First Non-small-cell Lung Carcinoma (NSCLC) Diagnosis by Tumor EGFR Mutation</title>
        <description>Number of months since the first diagnosis of NSCLC from informed consent date.</description>
        <time_frame>At Screening</time_frame>
        <population>Tumour Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>EGFR Mutation Positive</title>
            <description>Participants who were EGFR Mutation Positive for the analysis population.</description>
          </group>
          <group group_id="O2">
            <title>EGFR Mutation Negative</title>
            <description>Participants who were EGFR Mutation Negative for the analysis population.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Since First Non-small-cell Lung Carcinoma (NSCLC) Diagnosis by Tumor EGFR Mutation</title>
          <description>Number of months since the first diagnosis of NSCLC from informed consent date.</description>
          <population>Tumour Evaluable Population</population>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1051"/>
                <count group_id="O2" value="2164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="8.93"/>
                    <measurement group_id="O2" value="2.6" spread="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Organs With Metastasis by Tumour EGFR Mutation Status</title>
        <description>Summary of number of organs with metastasis. Only participants with at least 1 organ with metastasis are included.</description>
        <time_frame>At Screening</time_frame>
        <population>Tumour Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>EGFR Mutation Positive</title>
            <description>Participants who were EGFR Mutation Positive for the analysis population.</description>
          </group>
          <group group_id="O2">
            <title>EGFR Mutation Negative</title>
            <description>Participants who were EGFR Mutation Negative for the analysis population.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Organs With Metastasis by Tumour EGFR Mutation Status</title>
          <description>Summary of number of organs with metastasis. Only participants with at least 1 organ with metastasis are included.</description>
          <population>Tumour Evaluable Population</population>
          <units>Number</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="925"/>
                <count group_id="O2" value="1537"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.05"/>
                    <measurement group_id="O2" value="1.6" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Demographics and Disease Characteristics by Plasma EGFR Mutation Status</title>
        <description>Correlation of demographic and disease characteristics are summarized by EGFR mutation status with results from a multivariate logistic regression using stepwise forward selection with a 10% significance level for model entry.</description>
        <time_frame>At Screening</time_frame>
        <population>Plasma Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>EGFR Mutation Positive</title>
            <description>Participants who were EGFR Mutation Positive for the analysis population.</description>
          </group>
          <group group_id="O2">
            <title>EGFR Mutation Negative</title>
            <description>Participants who were EGFR Mutation Negative for the analysis population.</description>
          </group>
        </group_list>
        <measure>
          <title>Demographics and Disease Characteristics by Plasma EGFR Mutation Status</title>
          <description>Correlation of demographic and disease characteristics are summarized by EGFR mutation status with results from a multivariate logistic regression using stepwise forward selection with a 10% significance level for model entry.</description>
          <population>Plasma Evaluable Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="462"/>
                <count group_id="O2" value="2232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Histology: Adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="397"/>
                    <measurement group_id="O2" value="1417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histology: Non-adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Status: Never-Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298"/>
                    <measurement group_id="O2" value="835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Status: Ever-Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="1397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gender: Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="1575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gender: Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234"/>
                    <measurement group_id="O2" value="657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Region: Asia Pacific</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375"/>
                    <measurement group_id="O2" value="1378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Region: Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age: &lt;=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337"/>
                    <measurement group_id="O2" value="1454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age: &gt;65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WHO Performance Status: 0-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400"/>
                    <measurement group_id="O2" value="1956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WHO Performance Status: 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Disease Status: IIIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Disease Status: IIIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Disease Status: IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407"/>
                    <measurement group_id="O2" value="1597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Organs with Metastasis = 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Organs with Metastasis = 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Organs with Metastasis = 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Organs with Metastasis = 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Organs with Metastasis = 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Organs with Metastasis = 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Organs with Metastasis = 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <p_value_desc>Age: &lt;=65 vs. &gt;65</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% Significance Level for entry criteria</method_desc>
            <param_type>Wald Chi Square Statistic</param_type>
            <param_value>11.1060</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <p_value_desc>Age: &lt;=65 vs. &gt;65</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% Significance Level for model entry</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.561</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Number of Organs with Metastisis</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% Significance Level for entry criteria</method_desc>
            <param_type>Wald Chi Square Statistic</param_type>
            <param_value>34.1075</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Number of Organs with Metastisis</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% significance level for model entry</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.386</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Histology: Adenocarcinoma vs. Non-adenocarcinoma</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% Significance Level for entry criteria</method_desc>
            <param_type>Wald Chi Square Statistic</param_type>
            <param_value>14.0806</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Histology: Adenocarcinoma vs. Non-adenocarcinoma</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% Significance Level for model entry</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.955</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Smoking Status: Never-smoker vs. Ever-smoker</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% Significance Level for entry criteria</method_desc>
            <param_type>Wald Chi Square Statistic</param_type>
            <param_value>33.8574</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Smoking Status: Never-smoker vs. Ever-smoker</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% Significance Level for model entry</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.077</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Region: Asia Pacific vs. Russia</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% Significance Level for entry criteria</method_desc>
            <param_type>Wald Chi Square Statistic</param_type>
            <param_value>21.2537</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Region: Asia Pacific vs. Russia</p_value_desc>
            <method>Regression Stepwise</method>
            <method_desc>10% Significance Level for model entry</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.084</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Since First NSCLC Diagnosis by Plasma EGFR Mutation</title>
        <description>Number of months since the first diagnosis of NSCLC from informed consent date.</description>
        <time_frame>At Screening</time_frame>
        <population>Plasma Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>EGFR Mutation Positive</title>
            <description>Participants who were EGFR Mutation Positive for the analysis population.</description>
          </group>
          <group group_id="O2">
            <title>EGFR Mutation Negative</title>
            <description>Participants who were EGFR Mutation Negative for the analysis population.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Since First NSCLC Diagnosis by Plasma EGFR Mutation</title>
          <description>Number of months since the first diagnosis of NSCLC from informed consent date.</description>
          <population>Plasma Evaluable Population</population>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="462"/>
                <count group_id="O2" value="2232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="7.99"/>
                    <measurement group_id="O2" value="3.0" spread="11.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Organs With Metastasis by Plasma EGFR Mutation Status</title>
        <description>Summary of number of organs with metastasis. Only participants with at least 1 organ with metastasis are included.</description>
        <time_frame>At Screening</time_frame>
        <population>Plasma Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>EGFR Mutation Positive</title>
            <description>Participants who were EGFR Mutation Positive for the analysis population.</description>
          </group>
          <group group_id="O2">
            <title>EGFR Mutation Negative</title>
            <description>Participants who were EGFR Mutation Negative for the analysis population.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Organs With Metastasis by Plasma EGFR Mutation Status</title>
          <description>Summary of number of organs with metastasis. Only participants with at least 1 organ with metastasis are included.</description>
          <population>Plasma Evaluable Population</population>
          <units>Number</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="1607"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.21"/>
                    <measurement group_id="O2" value="1.6" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>First Line Treatment Choice by Asia Pacific Country</title>
        <time_frame>At Screening</time_frame>
        <population>Tumour Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>China</title>
            <description>Subjects in China that meet I/E and population criteria.</description>
          </group>
          <group group_id="O2">
            <title>Taiwan</title>
            <description>Subjects in Taiwan that meet I/E and population criteria</description>
          </group>
          <group group_id="O3">
            <title>South Korea</title>
            <description>Subjects in South Korea that meet I/E and population criteria</description>
          </group>
          <group group_id="O4">
            <title>Australia</title>
            <description>Subjects in Australia that meet I/E and population criteria</description>
          </group>
          <group group_id="O5">
            <title>Thailand</title>
            <description>Subjects in Thailand that meet I/E and population criteria</description>
          </group>
          <group group_id="O6">
            <title>Singapore</title>
            <description>Subjects in Singapore that meet I/E and population criteria</description>
          </group>
          <group group_id="O7">
            <title>Malaysia</title>
            <description>Subjects in Malaysia that meet I/E and population criteria</description>
          </group>
          <group group_id="O8">
            <title>Indonesia</title>
            <description>Subjects in Indonesia that meet I/E and population criteria</description>
          </group>
          <group group_id="O9">
            <title>Russia</title>
            <description>Subjects in Russia that meet I/E and population criteria</description>
          </group>
        </group_list>
        <measure>
          <title>First Line Treatment Choice by Asia Pacific Country</title>
          <population>Tumour Evaluable Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1391"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="100"/>
                <count group_id="O7" value="49"/>
                <count group_id="O8" value="273"/>
                <count group_id="O9" value="924"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systemic Anticancer Treatment: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1151"/>
                    <measurement group_id="O2" value="218"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="65"/>
                    <measurement group_id="O6" value="87"/>
                    <measurement group_id="O7" value="29"/>
                    <measurement group_id="O8" value="174"/>
                    <measurement group_id="O9" value="641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic Anticancer Treatment: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="99"/>
                    <measurement group_id="O9" value="283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Afatinib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bevacizumab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carboplatin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="52"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="100"/>
                    <measurement group_id="O9" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cetuximab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cisplatin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="424"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crizotinib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Docetaxel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erlotinib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Etoposide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gefitinib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="73"/>
                    <measurement group_id="O9" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gemcitabine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Icotinib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paclitaxel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="46"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pemetrexed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vincristine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vinorelbine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigational agent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1383"/>
                    <measurement group_id="O2" value="265"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="58"/>
                    <measurement group_id="O5" value="87"/>
                    <measurement group_id="O6" value="99"/>
                    <measurement group_id="O7" value="48"/>
                    <measurement group_id="O8" value="273"/>
                    <measurement group_id="O9" value="912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiotherapy: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiotherapy: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1329"/>
                    <measurement group_id="O2" value="245"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="84"/>
                    <measurement group_id="O6" value="89"/>
                    <measurement group_id="O7" value="32"/>
                    <measurement group_id="O8" value="266"/>
                    <measurement group_id="O9" value="852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1358"/>
                    <measurement group_id="O2" value="271"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="56"/>
                    <measurement group_id="O5" value="87"/>
                    <measurement group_id="O6" value="100"/>
                    <measurement group_id="O7" value="49"/>
                    <measurement group_id="O8" value="273"/>
                    <measurement group_id="O9" value="916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status</title>
        <time_frame>At Screening</time_frame>
        <population>Tumour Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>China-Mutation Status Positive</title>
            <description>Subjects in China that meet I/E and population criteria, who had a Positive Mutation Status.</description>
          </group>
          <group group_id="O2">
            <title>China-Mutation Status Negative</title>
            <description>Subjects in China that meet I/E and population criteria, who had a Negative Mutation Status.</description>
          </group>
          <group group_id="O3">
            <title>Taiwan-Mutation Status Positive</title>
            <description>Subjects in Taiwan that meet I/E and population criteria, who had a Positive Mutation Status.</description>
          </group>
          <group group_id="O4">
            <title>Taiwan-Mutation Status Negative</title>
            <description>Subjects in Taiwan that meet I/E and population criteria, who had a Negative Mutation Status.</description>
          </group>
          <group group_id="O5">
            <title>South Korea-Mutation Status Positive</title>
            <description>Subjects in South Korea that meet I/E and population criteria, who had a Positive Mutation Status.</description>
          </group>
          <group group_id="O6">
            <title>South Korea-Mutation Status Negative</title>
            <description>Subjects in South Korea that meet I/E and population criteria, who had a Negative Mutation Status.</description>
          </group>
          <group group_id="O7">
            <title>Australia-Mutation Status Positive</title>
            <description>Subjects in Australia that meet I/E and population criteria, who had a Positive Mutation Status.</description>
          </group>
          <group group_id="O8">
            <title>Australia-Mutation Status Negative</title>
            <description>Subjects in Australia that meet I/E and population criteria, who had a Negative Mutation Status.</description>
          </group>
          <group group_id="O9">
            <title>Thailand-Mutation Status Positive</title>
            <description>Subjects in Thailand that meet I/E and population criteria, who had a Positive Mutation Status.</description>
          </group>
          <group group_id="O10">
            <title>Thailand-Mutation Status Negative</title>
            <description>Subjects in Thailand that meet I/E and population criteria, who had a Negative Mutation Status.</description>
          </group>
          <group group_id="O11">
            <title>Singapore-Mutation Status Positive</title>
            <description>Subjects in Singapore that meet I/E and population criteria, who had a Positive Mutation Status.</description>
          </group>
          <group group_id="O12">
            <title>Singapore-Mutation Status Negative</title>
            <description>Subjects in Singapore that meet I/E and population criteria, who had a Negative Mutation Status.</description>
          </group>
          <group group_id="O13">
            <title>Malaysia-Mutation Status Positive</title>
            <description>Subjects in Malaysia that meet I/E and population criteria, who had a Positive Mutation Status.</description>
          </group>
          <group group_id="O14">
            <title>Malaysia-Mutation Status Negative</title>
            <description>Subjects in Malaysia that meet I/E and population criteria, who had a Negative Mutation Status.</description>
          </group>
          <group group_id="O15">
            <title>Indonesia-Mutation Status Positive</title>
            <description>Subjects in Indonesia that meet I/E and population criteria, who had a Positive Mutation Status.</description>
          </group>
          <group group_id="O16">
            <title>Indonesia-Mutation Status Negative</title>
            <description>Subjects in Indonesia that meet I/E and population criteria, who had a Negative Mutation Status.</description>
          </group>
          <group group_id="O17">
            <title>Russia-Mutation Status Positive</title>
            <description>Subjects in Russia that meet I/E and population criteria, who had a Positive Mutation Status.</description>
          </group>
          <group group_id="O18">
            <title>Russia-Mutation Status Negative</title>
            <description>Subjects in Russia that meet I/E and population criteria, who had a Negative Mutation Status.</description>
          </group>
        </group_list>
        <measure>
          <title>First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status</title>
          <population>Tumour Evaluable Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="567"/>
                <count group_id="O2" value="824"/>
                <count group_id="O3" value="130"/>
                <count group_id="O4" value="141"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="17"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="25"/>
                <count group_id="O10" value="62"/>
                <count group_id="O11" value="55"/>
                <count group_id="O12" value="45"/>
                <count group_id="O13" value="17"/>
                <count group_id="O14" value="32"/>
                <count group_id="O15" value="116"/>
                <count group_id="O16" value="157"/>
                <count group_id="O17" value="110"/>
                <count group_id="O18" value="814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systemic Anticancer Treatment? Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="499"/>
                    <measurement group_id="O2" value="652"/>
                    <measurement group_id="O3" value="122"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="32"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="32"/>
                    <measurement group_id="O9" value="19"/>
                    <measurement group_id="O10" value="46"/>
                    <measurement group_id="O11" value="54"/>
                    <measurement group_id="O12" value="33"/>
                    <measurement group_id="O13" value="10"/>
                    <measurement group_id="O14" value="19"/>
                    <measurement group_id="O15" value="80"/>
                    <measurement group_id="O16" value="94"/>
                    <measurement group_id="O17" value="86"/>
                    <measurement group_id="O18" value="555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic Anticancer Treatment? No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="172"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="16"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="12"/>
                    <measurement group_id="O13" value="7"/>
                    <measurement group_id="O14" value="13"/>
                    <measurement group_id="O15" value="36"/>
                    <measurement group_id="O16" value="63"/>
                    <measurement group_id="O17" value="24"/>
                    <measurement group_id="O18" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Afatinib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="10"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="13"/>
                    <measurement group_id="O18" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bevacizumab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carboplatin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="177"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="25"/>
                    <measurement group_id="O9" value="16"/>
                    <measurement group_id="O10" value="36"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="18"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="7"/>
                    <measurement group_id="O15" value="8"/>
                    <measurement group_id="O16" value="94"/>
                    <measurement group_id="O17" value="28"/>
                    <measurement group_id="O18" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cisplatin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="301"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="8"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="9"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="15"/>
                    <measurement group_id="O18" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crizotinib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Docetaxel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="3"/>
                    <measurement group_id="O18" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erlotinib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="16"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="3"/>
                    <measurement group_id="O18" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Etoposide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="8"/>
                    <measurement group_id="O17" value="18"/>
                    <measurement group_id="O18" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gefitinib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="21"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="4"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="73"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="24"/>
                    <measurement group_id="O18" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gemcitabine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="223"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="24"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="6"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="16"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="2"/>
                    <measurement group_id="O18" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Icotinib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paclitaxel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="33"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="4"/>
                    <measurement group_id="O16" value="14"/>
                    <measurement group_id="O17" value="18"/>
                    <measurement group_id="O18" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pemetrexed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="193"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="22"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="1"/>
                    <measurement group_id="O18" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vincristine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vinorelbine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="2"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigational Agent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="3"/>
                    <measurement group_id="O18" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cetuximab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                    <measurement group_id="O18" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="2"/>
                    <measurement group_id="O18" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="565"/>
                    <measurement group_id="O2" value="818"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="140"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="47"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="41"/>
                    <measurement group_id="O9" value="25"/>
                    <measurement group_id="O10" value="62"/>
                    <measurement group_id="O11" value="55"/>
                    <measurement group_id="O12" value="44"/>
                    <measurement group_id="O13" value="17"/>
                    <measurement group_id="O14" value="31"/>
                    <measurement group_id="O15" value="116"/>
                    <measurement group_id="O16" value="157"/>
                    <measurement group_id="O17" value="108"/>
                    <measurement group_id="O18" value="804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiotherapy: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="6"/>
                    <measurement group_id="O12" value="5"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="11"/>
                    <measurement group_id="O15" value="2"/>
                    <measurement group_id="O16" value="5"/>
                    <measurement group_id="O17" value="7"/>
                    <measurement group_id="O18" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiotherapy: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="546"/>
                    <measurement group_id="O2" value="783"/>
                    <measurement group_id="O3" value="128"/>
                    <measurement group_id="O4" value="117"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="37"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="30"/>
                    <measurement group_id="O9" value="23"/>
                    <measurement group_id="O10" value="61"/>
                    <measurement group_id="O11" value="49"/>
                    <measurement group_id="O12" value="40"/>
                    <measurement group_id="O13" value="11"/>
                    <measurement group_id="O14" value="21"/>
                    <measurement group_id="O15" value="114"/>
                    <measurement group_id="O16" value="152"/>
                    <measurement group_id="O17" value="103"/>
                    <measurement group_id="O18" value="749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="1"/>
                    <measurement group_id="O18" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="553"/>
                    <measurement group_id="O2" value="805"/>
                    <measurement group_id="O3" value="130"/>
                    <measurement group_id="O4" value="141"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="48"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="41"/>
                    <measurement group_id="O9" value="25"/>
                    <measurement group_id="O10" value="62"/>
                    <measurement group_id="O11" value="55"/>
                    <measurement group_id="O12" value="45"/>
                    <measurement group_id="O13" value="17"/>
                    <measurement group_id="O14" value="32"/>
                    <measurement group_id="O15" value="16"/>
                    <measurement group_id="O16" value="157"/>
                    <measurement group_id="O17" value="109"/>
                    <measurement group_id="O18" value="807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Not applicable - no safety data collected in the study</desc>
      <group_list>
        <group group_id="E1">
          <title>China</title>
          <description>Subjects in China that meet I/E and population criteria.</description>
        </group>
        <group group_id="E2">
          <title>Taiwan</title>
          <description>Subjects in Taiwan that meet I/E and population criteria</description>
        </group>
        <group group_id="E3">
          <title>South Korea</title>
          <description>Subjects in South Korea that meet I/E and population criteria</description>
        </group>
        <group group_id="E4">
          <title>Australia</title>
          <description>Subjects in Australia that meet I/E and population criteria</description>
        </group>
        <group group_id="E5">
          <title>Thailand</title>
          <description>Subjects in Thailand that meet I/E and population criteria</description>
        </group>
        <group group_id="E6">
          <title>Singapore</title>
          <description>Subjects in Singapore that meet I/E and population criteria</description>
        </group>
        <group group_id="E7">
          <title>Malaysia</title>
          <description>Subjects in Malaysia that meet I/E and population criteria</description>
        </group>
        <group group_id="E8">
          <title>Indonesia</title>
          <description>Subjects in Indonesia that meet I/E and population criteria</description>
        </group>
        <group group_id="E9">
          <title>Russia</title>
          <description>Subjects in Russia that meet I/E and population criteria</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Haiyi Jiang/Asia Medical Director</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+86 21 60302408</phone>
      <email>Haiyi.Jiang@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

